It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick ...

New techniques and devices made headway in tough treatment scenarios, and guidelines stressed the need for collaborative care ...

Researchers delved into the two “neutral” studies using Bayesian methods: a clearer picture of angiography’s role has emerged ...

Headlining the year’s developments were studies of catheter ablation and concomitant use of LAAO in patients with AF.

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

TCTMD's Yael Maxwell, Laura McKeown, Michael O'Riordan, Caitlin Cox, and Todd Neale describe their standout stories.

With new data from several studies this year, researchers are chipping away at the question of when to revascularize and how.

Mamas Mamas, Martha Gulati, and Benoy Shah review the most impactful CV research of the year.

One in 20 of the young adult participants had arrhythmias—some occurred many hours later when they were sobering up.

Mean CV health score, which ranges from 0 (worst) to 100 (best), was 82.6 in early childhood, 84.1 in mid-childhood, 82.0 in ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.